Significance of lymphovascular invasion in organ‐confined, node‐negative urothelial cancer of the bladder: data from the prospective p53‐MVAC trial. (25th March 2015)

• Record Type: Journal Article
• Authors: von Rundstedt, Friedrich‐Carl; Mata, Douglas A.; Groshen, Susan; Stein, John P.; Skinner, Donald G.; Stadler, Walter M.; Cote, Richard J.; Kryvenko, Oleksandr N.; Godoy, Guilherme; Lerner, Seth P.
• Is Part Of: BJU international. Volume 116:Number 1(2015:Jul.)
• Page Start: 44
• Page End: 49
• Publication Date: 2015-03-25
• Subjects: Genitourinary organs -- Diseases -- Periodicals; Genitourinary organs -- Surgery -- Periodicals; Urology -- Periodicals; 616.6
• DOI: 10.1111/bju.12997
• Languages: English
• ISSNs: 1464-4096

Abstract

<abstract abstract-type="main" id="bju12997-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="bju12997-sec-0001" sec-type="section"> <title>Objectives</title> <p>To investigate the association between lymphovascular invasion (LVI) and clinical outcome in organ‐confined, node‐negative urothelial cancer of the bladder (UCB) in a <italic>post hoc</italic> analysis of a prospective clinical trial. To explore the effect of adjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) on outcome in the subset of patients whose tumours exhibited LVI.</p> </sec> <sec id="bju12997-sec-0002" sec-type="section"> <title>Patients and Methods</title> <p>Surgical and tumour factors were extracted from the operative and pathology reports of 499 patients who had undergone radical cystectomy (RC) for pT1–T2 N0 UCB in the p53‐MVAC trial (Southwest Oncology Group 4B951/NCT00005047). The presence or absence of LVI was determined by pathological examination of transurethral resection or RC specimens. Variables were examined in univariate and multivariate Cox proportional hazards models for associations with time to recurrence (TTR) and overall survival (OS).</p> </sec> <sec id="bju12997-sec-0003" sec-type="section"> <title>Results</title> <p>Among 499 patients with a median follow‐up of 4.9 years, a subset of 102 (20%) had LVI‐positive tumours. Of these, 34 patients had pT1 and 68 had pT2 disease. LVI was significantly associated with TTR with a hazard ratio (HR) of 1.78 [95% confidence interval (CI) 1.15–2.77; number of events (EV) 95; <italic>P</italic> = 0.01) and with OS with a HR of 2.02 (95% CI 1.31–3.11; EV 98; <italic>P</italic> = 0.001) after adjustment for pathological stage. Among 27 patients with LVI‐positive tumours who were randomised to receive adjuvant chemotherapy, receiving MVAC was not significantly associated with TTR (HR 0.70, 95% CI 0.16–3.17; EV 7; <italic>P</italic> = 0.65) or with OS (HR 0.45, 95% CI 0.11–1.83; EV 9; <italic>P</italic> = 0.26).</p> </sec> <sec id="bju12997-sec-0004" sec-type="section"> <title>Conclusions</title> <p>Our <italic>post hoc</italic> analysis of the p53‐MVAC trial revealed an association between LVI and shorter TTR and OS in patients with pT1–T2N0 disease. The analysis did not show a statistically significant benefit of adjuvant MVAC chemotherapy in patients with LVI, although a possible benefit was not excluded.</p> </sec> </abstract>